Challenges and solutions in topical ocular drug- delivery systems

被引:57
作者
Ali, Maryam [1 ]
Byrne, Mark Edward [1 ]
机构
[1] Auburn Univ, Biomimet & Biohybrid Mat Biomed Devices & Drug De, Dept Chem Engn, Auburn, AL 36849 USA
关键词
drug delivery; extended drug delivery; noninvasive; ocular bioavailability; ophthalmic; permeation enhancer; residence time; topical delivery;
D O I
10.1586/17512433.1.1.145
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Vision significantly affects quality of life and the treatment of ocular disease poses a number of unique challenges. This review presents the major challenges faced during topical ocular drug administration and highlights strategies used to overcome the natural transport barriers of the eye. The circulation of tear fluid and aqueous humor decrease the residence time of topically delivered drugs, while ocular barriers in the corneal and conjuctival epithelia and the retinal pigment epithelium limit transport. Successful treatment strategies increase the residence time of drugs in the eye and/or enhance the ability of the drug to penetrate the ocular barriers and reach the target tissue. In this review, we discuss several drug-delivery strategies that have achieved clinical success or demonstrate high potential. We also draw attention to a number of excellent reviews that explore various ocular drug-delivery techniques in depth. Finally, we highlight cutting-edge drug-delivery technologies that improve the efficacy of current drug-delivery methods or use proven techniques to deliver novel therapeutics.
引用
收藏
页码:145 / 161
页数:17
相关论文
共 109 条
[71]  
*NAT EYE I, 2006, PROGR EYE VIS RES 19
[72]   PILOCARPINE INCORPORATED INTO A SUBMICRON EMULSION VEHICLE CAUSES AN UNEXPECTEDLY PROLONGED OCULAR HYPOTENSIVE EFFECT IN RABBITS [J].
NAVEH, N ;
MUCHTAR, S ;
BENITA, S .
JOURNAL OF OCULAR PHARMACOLOGY, 1994, 10 (03) :509-520
[73]   Anti-VEGF aptamer (pegaptanib) therapy for ocular vascular diseases [J].
Ng, Eugene W. M. ;
Adamis, Anthony P. .
OLIGONUCLEOTIDE THERAPEUTICS, 2006, 1082 :151-171
[74]   Retinal pigment epithelial tear following intravitreal injection of bevacizumab (Avastin) [J].
Nicolo, M. ;
Ghiglione, D. ;
Calabria, G. .
EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2006, 16 (05) :770-773
[75]  
Ogden J, 2006, DRUG DELIV REPORT
[76]   Eudragit RS100® nanosuspensions for the ophthalmic controlled delivery of ibuprofen [J].
Pignatello, R ;
Bucolo, C ;
Ferrara, P ;
Maltese, A ;
Puleo, A ;
Puglisi, G .
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2002, 16 (1-2) :53-61
[77]   Capacity and tolerance of a new device for ocular drug delivery [J].
Pijls, Rachel T. ;
Cruysberg, Lars P. J. ;
Nuijts, Rudy M. M. A. ;
Dias, Aylvin A. ;
Koole, Leo H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 341 (1-2) :152-161
[78]  
PRANKERD RJ, 1990, J PARENT SCI TECHN, V44, P139
[79]  
PRAUSE JU, 1986, SCAND J RHEUMATOL, P261
[80]   Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye [J].
Prausnitz, MR ;
Noonan, JS .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1998, 87 (12) :1479-1488